Spironolactone and Vaginal Dryness
Vaginal dryness is not a documented side effect of spironolactone in major guidelines or FDA labeling, but emerging clinical evidence suggests it may occur through anti-androgenic mechanisms that affect vulvovaginal tissue.
Evidence from Guidelines and FDA Labeling
The most comprehensive guideline evidence from the Journal of the American Academy of Dermatology 1 and the 2016 2 and 2024 3 AAD guidelines consistently list the following side effects of spironolactone:
- Menstrual irregularities (15-30%) - most common and dose-dependent
- Breast tenderness (3-5%)
- Dizziness (3-4%)
- Nausea (2-4%)
- Headache (2%)
- Polyuria (1-2%)
- Fatigue (1-2%)
Notably, vaginal dryness is not mentioned in any of these comprehensive side effect profiles. The FDA drug label 4 similarly does not list vaginal dryness as a recognized adverse effect.
Emerging Clinical Evidence
However, a 2019 case series provides direct clinical evidence that spironolactone can cause vulvovaginal atrophy and associated symptoms 5. This study documented 7 women taking spironolactone who developed:
- Vulvar vestibular atrophy and tenderness
- Introital dyspareunia (painful intercourse)
- Decreased sexual arousal
- Vaginal dryness symptoms
All patients improved after discontinuing spironolactone and applying topical estradiol 0.01%/testosterone 0.1% gel to the vestibule twice daily 5. This represents the strongest direct evidence linking spironolactone to vaginal dryness.
A 2002 review also noted that spironolactone may cause decreased libido and impaired lubrication 6, though this was based on limited data at the time.
Mechanistic Explanation
The biological plausibility is strong: spironolactone's anti-androgenic effects block androgen receptors throughout the body, including in vulvovaginal tissue 5. Androgens play a role in maintaining vaginal tissue health, lubrication, and sexual function. By blocking these receptors, spironolactone may induce a state of relative androgen deficiency in genital tissues, similar to what occurs in menopause.
Clinical Implications and Management
When to Suspect Spironolactone-Related Vaginal Dryness
Consider this diagnosis in women taking spironolactone who report:
- New-onset vaginal dryness
- Painful intercourse (especially at the introitus)
- Decreased sexual arousal
- Vulvar discomfort
Management Algorithm
First-line approach: Discontinue spironolactone if clinically feasible (consider alternative acne treatments like oral contraceptives or isotretinoin)
If spironolactone must be continued: Apply topical estradiol/testosterone gel to the vestibule twice daily 5
Alternative: Consider vaginal estrogen therapy alone, though the case series specifically used combination estradiol/testosterone
Monitor response: Symptoms should improve within weeks to months of intervention
Important Caveats
- This is an underrecognized side effect - the medical literature is sparse, and most providers are unaware of this association 5, 6
- The true incidence is unknown since it's not systematically tracked in clinical trials
- Do not dismiss patient complaints of vaginal dryness while on spironolactone, even though it's not in official labeling
- Recent studies on skin biophysical properties showed spironolactone did not impair skin barrier function or hydration 7, but these studies did not specifically assess vulvovaginal tissue
Bottom Line
While vaginal dryness is not listed as an official side effect in guidelines or FDA labeling, clinical evidence demonstrates that spironolactone can cause vulvovaginal atrophy and dryness through its anti-androgenic effects 5. Providers should counsel patients about this possibility and be prepared to manage it with either medication discontinuation or topical hormone therapy.